NASDAQ:BBIO BridgeBio Pharma Q3 2026 Earnings Date & Estimates $68.56 +0.44 (+0.65%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$68.57 +0.01 (+0.01%) As of 10/23/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. BridgeBio Pharma is estimated to report Q3 2026 earnings on Thursday, October 29, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateOctober 29, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from BridgeBio Pharma in Q3 2026BridgeBio Pharma is expected to post earnings of -$0.5389 per share on revenue of $293.48 million. In the same quarter a year earlier BridgeBio Pharma reported -$0.95 per share on revenue of $120.70 million. BridgeBio Pharma last reported on August 10, 2026, posting -$0.78 per share and missing the -$0.5756 consensus estimate. BridgeBio Pharma has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.5389Expected Revenue$293.48 millionPrior-Year EPS-$0.95Prior-Year Revenue$120.70 millionExpected Revenue Growth+143.1%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.78 (Missed by -$0.2044)Last Quarter Revenue$243.68 millionEPS Beat Rate2 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report BridgeBio Pharma Q3 2026 Earnings FAQ When does BridgeBio Pharma report Q3 2026 earnings? BridgeBio Pharma (NASDAQ:BBIO) is estimated to report Q3 2026 earnings on Thursday, October 29, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is BridgeBio Pharma's Q3 2026 earnings call? BridgeBio Pharma's Q3 2026 earnings conference call is scheduled for Thursday, October 29, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for BridgeBio Pharma? Analysts expect BridgeBio Pharma to post earnings of -$0.5389 per share for Q3 2026. How much revenue is BridgeBio Pharma expected to report? The consensus revenue estimate for BridgeBio Pharma is $293.48 million for Q3 2026. BridgeBio Pharma Earnings HeadlinesBridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ETOctober 22 at 8:00 AM | globenewswire.comBridgeBio Pharma (BBIO) Projected to Post Earnings on WednesdayOctober 21 at 3:42 AM | americanbankingnews.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 24 at 1:00 AM | The Oxford Club (Ad)BridgeBio Pharma (NASDAQ:BBIO) Stock Price Target Cut by CitigroupOctober 21 at 1:18 AM | americanbankingnews.comWhere Does BridgeBio Pharma (BBIO) Value Sit After Trial Wins?October 20, 2026 | finance.yahoo.comBridgeBio Pharma (BBIO) Draws Fresh Attention, Is The Pullback A Valuation Opportunity?October 20, 2026 | finance.yahoo.comSee More BridgeBio Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BridgeBio Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BridgeBio Pharma and other key companies, straight to your email. Email Address About BridgeBio PharmaBridgeBio Pharma (NASDAQ:BBIO) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company operates through a portfolio of subsidiary and affiliated biotechnology businesses, with research programs spanning rare diseases, oncology, cardiology and other conditions linked to underlying genetic or molecular causes. BridgeBio’s portfolio includes therapies designed to address the root mechanisms of disease rather than primarily treating symptoms. Its products and investigational programs have included medicines for transthyretin amyloidosis, genetic endocrine disorders, neurological diseases and certain cancers. The company’s acoramidis product, marketed as Attruby, was approved in the United States for adults with wild-type or hereditary transthyretin-mediated amyloid cardiomyopathy. Founded in 2015, BridgeBio is headquartered in Palo Alto, California, and advances its programs through research, clinical development, regulatory and commercial activities in the United States and international markets. The company is led by founder and Chief Executive Officer Neil Kumar, who has overseen BridgeBio’s portfolio-based approach to developing treatments for patients with significant unmet medical needs.View BridgeBio Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestSpotify Soars After Earnings as the Company Touts AI Benefits and Moderating CostsPalantir's Next Big Test Isn't a Partnership—It's the NumbersKinder Morgan's $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings BeatCapital One Earnings: After a Double Beat the Rally Is OnTractor Supply's Q3 Beat Plants the Seeds for a Stock ReboundWD-40 Could Reward Patient Investors—Here's Why Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
